LA JOLLA PHARMACEUTICAL COMPANY Inactive Instrument
La Jolla Pharmaceutical Company
Equities
LJPC
US5034596040
Biotechnology & Medical Research
Presentation Operator MessageOperator (Operator)Welcome to the La Jolla Pharmaceutical Company...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
La Jolla Pharmaceutical Company is primarily engaged in the commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
| 1st Jan change | Capi. | |
|---|---|---|
| +7.12% | 111B | |
| +10.36% | 106B | |
| -12.36% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -9.29% | 16.81B | |
| +38.79% | 12.54B | |
| -25.15% | 8.09B |
